Intermediate Risk Prostate Cancer

  • PSA 10-20
  • Gleason 3+4 or 4+3
  • Clinical Exam: Abnormality that does not extend beyond the boundary of the prostate

Management Options

Clinical Trials


© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved. Disclaimer
Email: | 600 North Wolfe Street, Baltimore, Maryland 21287

urology second opinion urology second opinion